{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:50:42Z","timestamp":1773661842120,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,2,8]],"date-time":"2006-02-08T00:00:00Z","timestamp":1139356800000},"content-version":"vor","delay-in-days":3997,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[1995,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We synthesized <jats:sup>14<\/jats:sup>C\u2010warfarin hexadecyl ether (<jats:sup>14<\/jats:sup>C\u2010WHE) by addition of a palmityl moiety to the hydroxyl group at the 4\u2010position of <jats:sup>14<\/jats:sup>C\u2010warfarin, a compound known to bind to serum albumin. <jats:sup>14<\/jats:sup>C\u2010WHE preferentially bound to the lipoproteins, low\u2010density lipoprotein (LDL) and high\u2010density lipoprotein (HDL), in mouse plasma both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo.<\/jats:italic> <jats:sup>14<\/jats:sup>C\u2010Warfarin mainly concentrated in the liver immediately after intravenous administration to mice bearing M5076 sarcoma, and was found at only low concentrations in other tissues including the tumour. <jats:sup>14<\/jats:sup>C\u2010WHE highly distributed to the tumour, in other tissues including the tumour. <jats:sup>14<\/jats:sup>C\u2010WHE highly distributed to the tumour, adrenal, and spleen, as well as the liver. These tissues coincided with those in which human <jats:sup>125<\/jats:sup>I\u2010LDL was vigorously incorporated. The results indicate that chemical modification of an agent, giving it high lipophilicity, will enable it to bind to lipoproteins after intravenous administration. These modifications raise the possibility of lipoproteins as endogenous targeting carriers into tumour cells, which have high LDL\u2010receptor activity.<\/jats:p>","DOI":"10.1002\/bdd.2510160204","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T10:02:02Z","timestamp":1160820122000},"page":"91-103","source":"Crossref","is-referenced-by-count":14,"title":["Plasma lipoproteins as targeting carriers to tumour tissues after administraion of a lipophilic agent to mice"],"prefix":"10.1002","volume":"16","author":[{"given":"Taro","family":"Tokui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitose","family":"Kuroiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Tokui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Sasagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Komai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3513311"},{"key":"e_1_2_1_3_2","first-page":"322","volume":"26","author":"Urien S.","year":"1984","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1982.tb06206.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105468"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(83)90325-2"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198005030-00004"},{"key":"e_1_2_1_8_2","first-page":"485","volume":"43","author":"Shu H. P.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_9_2","first-page":"175","volume-title":"Lipoproteins as Carriers of Pharmacological Agents","author":"Peterson C. O.","year":"1991"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686259"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90679-F"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.367"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686010"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(81)90952-2"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(84)80046-4"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(89)90236-1"},{"key":"e_1_2_1_17_2","first-page":"6244","volume":"52","author":"Vitols S.","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.46.070177.004341"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510150202"},{"key":"e_1_2_1_20_2","first-page":"381","volume":"46","author":"Tsuruo T.","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.66"},{"key":"e_1_2_1_22_2","first-page":"824","volume":"11","author":"Sudlow G.","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103182"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(72)90034-3"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-2797(86)80082-5"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.4.879"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)34780-5"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112460"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1983.63.4.1536"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(94)90250-X"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0021-9258(19)70270-1","volume":"255","author":"Innerarity T. L.","year":"1980","journal-title":"J. Biol. Chem."}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2510160204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2510160204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T14:35:45Z","timestamp":1695825345000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2510160204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["10.1002\/bdd.2510160204"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2510160204","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}